Lung cancer with dual <i>EGFR</i> and <i>ALK</i> driver alterations at baseline: a retrospective observational cohort study-Reference-Cited by-同舟云学术

Lung cancer with dual EGFR and ALK driver alterations at baseline: a retrospective observational cohort study

Published:2022-08-16 Issue:9 Volume:61 Page:1143-1147
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Noronha Vanita¹,Chougule Anuradha¹,Chandrani Pratik¹,Kaushal Rajiv Kumar¹,Patil Vijay Maruti¹,Menon Nandini¹,Kapoor Akhil²,Chopade Sunil¹,Singh Ajaykumar¹,Shetty Omshree¹,Dutt Amit¹,Banavali Shripad¹,Prabhash Kumar¹

Affiliation:

1. Tata Memorial Center, Homi Bhabha National Institute, Mumbai, India

2. Homi Bhabha Cancer Hospital, Varanasi, India

Publisher

Informa UK Limited

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2022.2109426

Reference25 articles.

1. Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management

2. Treatment of advanced non-small-cell lung cancer: First line, maintenance, and second line– Indian consensus statement update(Under the aegis of Lung Cancer Consortium Asia, Indian Cooperative Oncology Network, Indian Society of Medical and Pediatric Oncology, Molecular Oncology Society, and Association of Physicians of India)

3. Coexistence of epidermal growth factor receptor mutation and anaplastic lymphoma kinase translocation in non-small cell lung cancer: Do we know the treatment sequence?

4. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer;Frontiers in Pharmacology;2023-08-29

2. Lung Cancer Detection using Transfer Learning and EfficientNet B2 Architecture;2023 International Conference on Disruptive Technologies (ICDT);2023-05-11

3. ALK-driven NSCLC: A narrative review - Part I;Cancer Research, Statistics, and Treatment;2023